Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RAD52 | P43351 | 1/20 | 0.56 |
| ▸ | MAPT | P10636 | 3/20 | 0.54 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.54 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.54 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.54 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.54 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.54 |
| ▸ | ALOX12 | P18054 | 1/20 | 0.54 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.54 |
| ▸ | HTT | P42858 | 1/20 | 0.54 |
| ▸ | SYK | P43405 | 1/20 | 0.50 |
| ▸ | PLK4 | O00444 | 1/20 | 0.50 |
| ▸ | AURKA | O14965 | 4/20 | 0.48 |
| ▸ | DHFR | P00374 | 1/20 | 0.48 |
| ▸ | LMNA | P02545 | 1/20 | 0.48 |
| ▸ | TSHR | P16473 | 1/20 | 0.48 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.47 |
| ▸ | NPC1 | O15118 | 2/20 | 0.47 |
| ▸ | RAB9A | P51151 | 2/20 | 0.47 |
| ▸ | USP2 | O75604 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL24270329 | 0.80 | SYK (0.58) | RAD52MAPTL3MBTL1ALDH1A1CYP1A2 | |
| SCHEMBL10592821 | 0.80 | RAD52 (0.54) | RAD52MAPTL3MBTL1ALDH1A1CYP1A2 | |
| SCHEMBL23780649 | 0.79 | SCN9A (0.72) | RAD52MAPTALOX12SYKPLK4 | |
| SCHEMBL7512302 | 0.78 | RAD52 (0.56) | RAD52MAPTL3MBTL1ALDH1A1CYP1A2 | |
| SCHEMBL911 | 0.78 | AURKA (0.63) | MAPTL3MBTL1ALDH1A1ALOX12SYK | |
| SCHEMBL15968669 | 0.78 | AURKA (0.63) | MAPTL3MBTL1ALDH1A1ALOX12SYK | |
| SCHEMBL4894535 | 0.78 | SYK (0.62) | SYKPLK4AURKACDK1CDK2 | |
| SCHEMBL4498501 | 0.77 | AURKA (0.63) | MAPTALDH1A1HTTSYKAURKA | |
| SCHEMBL3786298 | 0.77 | HPGD (0.54) | MAPTALDH1A1LMNATSHRNPC1 | |
| SCHEMBL1120994 | 0.77 | PIK3CG (0.51) | MAPTALDH1A1ALOX12SYKPLK4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7449465-B2 | Triazolopyrimidine derivatives as glycogen synthase kinase 3 inhibitors | JANSSEN PHARMACEUTICA, N.V. (BE) | 2008-11-11 | — | — | US | disclosed |
| US-7449465-B2 | Triazolopyrimidine derivatives as glycogen synthase kinase 3 inhibitors | JANSSEN PHARMACEUTICA, N.V. (BE) | 2008-11-11 | — | — | US | disclosed |
| EP-1781659-B1 | TRIAZOLOPYRIMIDINE DERIVATIVES AS GLYCOGEN SYNTHASE KINASE 3 INHIBITORS | JANSSEN PHARMACEUTICA NV (BE) | 2008-11-05 | — | — | EP | disclosed |
| US-20080176866-A1 | 3-(5-Bromo-2-{4-[5-bromo-4-((1R,2R)-2-hydroxy-1-methyl propylamino)-pyrimidin-2-ylamino]phenylamino}pyrimidin-4-ylamino)butan-2-ol; cell cycle and tyrosine kinase receptor inhibitor; antiproliferative, anticarcinogenic agent | BAYER SCHERING PHARMA AG (DE) | 2008-07-24 | — | — | US | disclosed |
| US-20080176866-A1 | 3-(5-Bromo-2-{4-[5-bromo-4-((1R,2R)-2-hydroxy-1-methyl propylamino)-pyrimidin-2-ylamino]phenylamino}pyrimidin-4-ylamino)butan-2-ol; cell cycle and tyrosine kinase receptor inhibitor; antiproliferative, anticarcinogenic agent | BAYER SCHERING PHARMA AG (DE) | 2008-07-24 | — | — | US | disclosed |
| US-20080176866-A1 | 3-(5-Bromo-2-{4-[5-bromo-4-((1R,2R)-2-hydroxy-1-methyl propylamino)-pyrimidin-2-ylamino]phenylamino}pyrimidin-4-ylamino)butan-2-ol; cell cycle and tyrosine kinase receptor inhibitor; antiproliferative, anticarcinogenic agent | BAYER SCHERING PHARMA AG (DE) | 2008-07-24 | — | — | US | disclosed |
| EP-1939185-A1 | New types of hetaryl-phenylendiamin-pyrimidines as protein kinase inhibitors for the treatment of cancer | Bayer Schering Pharma Aktiengesellschaft (DE) | 2008-07-02 | — | — | EP | disclosed |
| EP-1939185-A1 | New types of hetaryl-phenylendiamin-pyrimidines as protein kinase inhibitors for the treatment of cancer | Bayer Schering Pharma Aktiengesellschaft (DE) | 2008-07-02 | — | — | EP | disclosed |
| WO-2008074515-A1 | NOVEL HETARYL-PHENYLENE-DIAMINE PYRIMIDINE AS PROTEIN KINASE INHIBITORS | BAYER SCHERING PHARMA AKTIENGESELLSCHAFT (DE) | 2008-06-26 | — | — | WO | disclosed |
| WO-2008074515-A1 | NOVEL HETARYL-PHENYLENE-DIAMINE PYRIMIDINE AS PROTEIN KINASE INHIBITORS | BAYER SCHERING PHARMA AKTIENGESELLSCHAFT (DE) | 2008-06-26 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080176866-A1 | 3-(5-Bromo-2-{4-[5-bromo-4-((1R,2R)-2-hydroxy-1-methyl propylamino)-pyrimidin-2-ylamino]phenylamino}pyrimidin-4-ylamino)butan-2-ol; cell cycle and tyrosine kinase receptor inhibitor; antiproliferative, anticarcinogenic agent | CDK2, MKI67, ERBB2 | RAD52 1284/4885MAPT 4836/4885L3MBTL1 4162/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.